A multinational research team led by Assistant Professor Shady Farah of the Technion–Israel Institute of Technology has unveiled an implantable device that could eliminate the need for daily insulin injections for diabetes patients. According to Ynet, the implant functions as an “artificial pancreas,” continuously monitoring blood sugar levels and producing insulin as needed.
The breakthrough centers on a novel protective technology researchers call a “crystalline shield”, engineered to prevent the body’s immune system from rejecting the implant — a major hurdle that has stymied cell‑based therapies for decades. The shield allows the implant to operate reliably for years.
Tests in mice showed effective long‑term glucose regulation, and studies in non‑human primates confirmed that the cells inside the implant remain viable and functional, the researchers said. Those results, they added, provide strong support for future clinical testing in humans.
While the primary purpose of this implant is to manage diabetes, the team says the same platform could be adapted to create implants for treating chronic and genetic conditions such as hemophilia. Drug regimens could be replaced with self-regulating, automated devices, making lifelong illnesses more manageable.
Technion, formally known as the Israel Institute of Technology, is one of the nation’s oldest universities, with science and medicine as its primary fields of study. U.S. universities that collaborated on the research include the Massachusetts Institute of Technology, Harvard University, Johns Hopkins University, and the University of Massachusetts.